Investment Summary

Precigen Invests In Exemplar Genetics

On January 26, 2015, Precigen invested in life science company Exemplar Genetics

Investment Highlights
  • This is Precigen’s 5th transaction in the Life Science sector.
  • This is Precigen’s 4th transaction in the United States.
  • This is Precigen’s 2nd transaction in Iowa.

Investment Summary
Date 2015-01-26
Target Exemplar Genetics
Sector Life Science
Investor(s) Precigen
Deal Type Stake Purchase

Target

Exemplar Genetics

Sioux Center, Iowa, United States
website
Exemplar Genetics LLC is a provider of models and services that aid scientists in the development of next-generation procedures, devices and therapeutics.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

Investor

Precigen

Germantown, Maryland, United States

website

Category Company
Founded 1998
Sector Life Science
Employees423
Revenue 103M USD (2020)
DESCRIPTION

Precigen is engaged to create biologically based products and processes that improve the quality of life and health of the planet. The science underlying these products is known as synthetic biology – an engineered approach to the field of biology. Precigen was founded in 1998 and is based in Germantown, Maryland.

DEAL STATS #
Overall 5 of 10
Sector (Life Science) 5 of 9
Type (Stake Purchase) 1 of 1
State (Iowa) 2 of 2
Country (United States) 4 of 6
Year (2015) 1 of 4
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2014-07-01 Trans Ova Genetics LC

Sioux Center, Iowa, United States

Trans Ova Genetics LC is a provider of bovine reproductive technologies. Company Genetics provides industry-leading reproductive technologies and expertise to cattle breeders through a unique professional services team that works closely with clients to understand their breeding goals, and ultimately help clients advance and extend superior genetics.

Buy $60M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-02-13 ActoGeniX NV

Zwijnaarde, Belgium

ActoGenix develops therapies, based on its patented TopAct™ technology platform, which address major diseases requiring intensive medical care, including gastrointestinal problems, auto-immunity diseases, allergies and metabolic disorders. TopAct™ uses micro-organisms for the oral administration of proteins. ActoGeniX’s first product – for treating Crohn’s disease - has already been successfully tested on patients.

Buy $60M
Mergr

Product

Company

Legal